Purification and characterization of rhesus monkey liver amido hydrolases and their roles in the metabolic polymorphism for E6123, a platelet-activating factor receptor antagonist

Drug Metabolism and Disposition

Volumn 24, Issue 11, 1996, Pages 1186-1191

  Kusano, Kazutomi ^a   Seko, Takayuki ^a   Tanaka, Shigeru ^a   Shikata, Yasushi ^a   Ando, Tomomi ^a   Ida, Satoshi ^a   Hosokawa, Masakiyo ^b   Satoh, Tetsuo ^b   Yuzuriha, Teruaki ^a   Horie, Toru ^a  

^a EISAI CO LTD   (Japan)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

6 (2 CHLOROPHENYL) 9 CYCLOPROPYLCARBONYL 7,8,9,10 TETRAHYDRO 1,4 DIMETHYL 4H PYRIDO[4',3':4,5]THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE; AMIDASE; CARBOXYLESTERASE; HYDROXYAPATITE; LIVER ENZYME; LUBROL; SEPHAROSE; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DRUG HYDROLYSIS; DRUG METABOLISM; ENZYME CHEMISTRY; ENZYME KINETICS; ENZYME PURIFICATION; ENZYME SPECIFICITY; GENETIC POLYMORPHISM; INTRAVENOUS DRUG ADMINISTRATION; LIVER MICROSOME METABOLISM; MALE; MICHAELIS CONSTANT; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY;

AMIDOHYDROLASES; AMINO ACID SEQUENCE; ANIMALS; AZEPINES; CHROMATOGRAPHY, LIQUID; ELECTROPHORESIS, POLYACRYLAMIDE GEL; LIVER; MACACA MULATTA; MALE; MOLECULAR SEQUENCE DATA; MOLECULAR WEIGHT; PLATELET MEMBRANE GLYCOPROTEINS; POLYMORPHISM, GENETIC; RECEPTORS, CELL SURFACE; RECEPTORS, G-PROTEIN-COUPLED; SEQUENCE HOMOLOGY, AMINO ACID; SUBSTRATE SPECIFICITY; TRIAZOLES;

ANIMALIA; MACACA MULATTA;

EID: 8044249423     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. D. A. P. Evans, K. A. Manly, and V. A. McKusick: Genetic control of isoniazid metabolism in man. Br. Med. J. 2, 485-491 (1960).
2. M. Blum, A. Demierre, D. M. Grant, M. Heim, and U. A. Meyer: Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc. Natl. Acad. Sci. USA 88, 5237-5241 (1991).
3. M. Eichelbaum, N. Spannbucker, and H. J. Dengler: Influence of the defective metabolism of sparteine on its pharmacokinetics. Eur. J. Clin. Pharmacol. 16, 189-194 (1979).
4. A. Kupfer, and R. Preisig: Pharmacokinetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur. J. Clin. Pharmacol. 26, 753-759 (1984).
5. H. Tsunoda, Y. Sakuma, K. Harada, K. Muramoto, S. Katayama, T. Horie, M. Shimomura, R. Clark, S. Miyazawa, K. Okano, Y. Machida, K. Katayama, and I. Yamatsu: Pharmacological activities of a novel triazolodiazepine derivative as a platelet-activating factor antagonist. Arzneim. Forsch. 40, 1201-1205 (1990).
6. Y. Sakuma, K. Muramoto, S. Harada, S. Katayama, H. Tsunoda, and K. Katayama: Inhibitory effects of a novel PAF antagonist, E6123, on anaphylactic responses in passively and actively sensitized guinea pigs and passively sensitized mice. Prostaglandins 42, 541-555 (1991).
7. K. Kusano, S. Tanaka, Y. Abe, S. Ida, and T. Yuzuriha: Pharmacokinetics of a new thienodiazepine platelet activating factor receptor antagonist (E6123) in laboratory animals: is there a metabolic polymorphism in rhesus monkeys? Xenobiotica 23, 589-598 (1993).
8. M. V. Relling: Polymorphic drug metabolism. Clin. Pharmacol. 8, 852-863 (1989).
9. K. Kusano, S. Tanaka, T. Ando, Y. Abe, S. Ida, and T. Yuzuriha: Metabolic polymorphism of E6123 in rhesus monkey. Xenobiotica 23, 599-608 (1993).
10. E. Heymann: Carboxylesterases and amidases. In "Enzymatic Basis of Detoxication" (W. B. Jackson, ed.), vol. 2, pp. 291-323. Academic Press, New York, 1980.
11. S. Miyazawa, K. Okano, N. Shimomura, T. Kawahara, O. Asano, H. Yoshimura, T. Kawai, S. Souda, Y. Yoshida, T. Sato, Y. Machida, and I. Yamatsu: A practical synthesis of optically active platelet-activating factor antagonist, (+)-6-(2-chlorophenyl)-3-cyclopropanecarbonyl-8,11-dimethyl-2,3,4,5-tetrahydro- 8H-pyrido[4′,3′:4,5]thieno[3,2-f] [1,2,4]triazolo[4,3-a][1,4]diazepine (E6123), and its absolute configuration. Chem. Pharm. Bull. (Tokyo) 40, 521-523 (1992).
12. F. P. Guengerich and M. V. Martin: Purification of cytochrome P-450, NADPH-cytochrome P-450 reductase, and epoxide hydratase from a single preparation of rat liver microsomes. Arch. Biochem. Biophys. 205, 365-379 (1980).
13. M. Hosokawa, T. Maki, and T. Satoh: Characterization of molecular species of liver microsomal carboxylesterase of several animal species and humans. Arch. Biochem. Biophys. 277, 219-227 (1990).
14. U. K. Laemmli: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond.) 227, 680-685 (1970).
15. W. Wray, T. Boulikas, V. P. Wray, and R. Hancock: Silver staining ofproteins in polyacrylamide gels. Anal. Biochem. 118, 197-203 (1981).
16. M. R. Probst, J. Paul, and U. A. Meyer: Purification and characterization of a human liver arylacetamide deacetylase. Biochem. Biophys. Res. Commun. 177, 453-459 (1991).
17. M. R. Probst, M. Beer, D. Beer, P. Jeno, U. A. Meyer, and R. Gasser: Human liver arylacetamide deacetylase. J. Biol. Chem. 269, 21650-21656 (1994).
18. K. Shirai, I. Ohsawa, Y. Saito, and S. Yoshida: Effect of phospholipids on hydrolysis of trioleoylglycerol by human serum carboxylesterase. Biochem. Biophys. Acta 962, 377-383 (1988).
19. E. Steiner, L. Bertilsson, J. Sawe, I. Bertling, and F. Sjoqvist: Polymorphic debrisoquine hydroxylation in 757 Swedish subjects. Clin. Pharmacol. Ther. 44, 431-435 (1988).
20. D. A. P. Evans: N-Acetyltransferase. Pharmacol. Ther. 42, 157-234 (1989).
21. J. Mordenti: Man versus beast: pharmacokinetic scaling in animals. J. Pharm. Sci. 75, 1028-1040 (1986).